Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)

AIDS

Volumn 29, Issue 18, 2015, Pages 2419-2426

  Andrade, Adriana ^a   Guedj, Jeremie ^b,c   Rosenkranz, Susan L ^d   Lu, Darlene ^d   Mellors, John ^e   Kuritzkes, Daniel R ^f   Perelson, Alan S ^g   Ribeiro, Ruy M ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

ACTG 5248 study; ACTG 5249 substudy; Emtricitabine; Integrase inhibitor; Mathematical model; Plasma HIV RNA; Raltegravir; Tenofovir disoproxil fumarate; Viral decay; Viral dynamics; Viral kinetics

Indexed keywords

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CELL LOSS; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MATHEMATICAL MODEL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; REVERSE TRANSCRIPTION; RNA DEGRADATION; VIRUS LOAD; BLOOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; PLASMA; PROCEDURES; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; RALTEGRAVIR POTASSIUM; RNA, VIRAL; VIRAL LOAD;

EID: 84956842638     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000843     Document Type: Article

References (40)

1. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002;2:28-36.
2. Perelson AS, Ribeiro RM. Modeling the within-host dynamics of HIV infection. BMC Biol 2013;11:96.
3. Ribeiro RM, Perelson AS. Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. J Hepatol 2002;37:277-279.
4. Layden TJ, Layden JE, Ribeiro RM, Perelson AS. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin Liver Dis 2003;7:163-178.
5. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol 2006;80:7590-7599.
6. Nowak MA, May RM. Virus dynamics: mathematical principles of immunology and virology. Oxford: Oxford University Press; 2000.
7. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
8. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen [see comments]. AIDS 1998;12:1483-1490.
9. Dornadula G, Zhang H, Van Uitert B, Stern J, Livornese L Jr, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-1632.
10. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007;3:e46.
11. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008;105:3879-3884.
12. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008;105:4832-4837.
13. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-532.
14. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-133.
15. De Jesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5.
16. Min S, Sloan L, De Jesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25:1737-1745.
17. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis 2013;208:884-891.
18. Lennox JL, De Jesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806.
19. Rockstroh JK, De Jesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63:77-85.
20. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-515.
21. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21:2315-2321.
22. Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, et al. Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses 2011;27:759-761.
23. Gilmore JB, Kelleher AD, Cooper DA, Murray JM. Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action. PLoS Comput Biol 2013;9:e1002971.
24. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003;77:5037-5038.
25. Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003;187:896-900.
26. Murray JM, Kelleher AD, Cooper DA. Timingofthe components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals. J Virol 2011;85:10798-10805.
27. Samson A, Lavielle M, Mentre F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model. Computat Stat Data Anal 2006;51:1562-1574.
28. Thiebaut R, Guedj J, Jacqmin-Gadda H, Chene G, Trimoulet P, Neau D, et al. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol 2006;6:38.
29. Mohammadi P, Desfarges S, Bartha I, Joos B, Zangger N, Munoz M, et al. 24h in the life of HIV-1 in a T cell line. PLoS Pathog 2013;9:e1003161.
30. Borghans JA, de Boer RJ. Quantification of T-cell dynamics: from telomeres to DNA labeling. Immunol Rev 2007;216:35-47.
31. Ribeiro RM, Mohri H, Ho DD, Perelson AS. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci USA 2002;99:15572-15577.
32. Vrisekoop N, den Braber I, de Boer AB, Ruiter AF, Ackermans MT, van der Crabben SN, et al. Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc Natl Acad Sci USA 2008;105:6115-6120.
33. Westera L, Drylewicz J, den Braber I, Mugwagwa T, van der Maas I, Kwast L, et al. Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood 2013;122:2205-2212.
34. Althaus CL, De Boer RJ. Implications of CTL-mediated killing of HIV-infected cells during the nonproductive stage of infection. PLoS One 2011;6:e16468.
35. Sacha JB, Buechler MB, Newman LP, Reed J, Wallace LT, Loffredo JT, et al. Simian immunodeficiency virus-specific CD8+ T cells recognize Vpr- and Rev-derived epitopes early after infection. J Virol 2010;84:10907-10912.
36. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007;178:2746-2754.
37. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, Spencer SP, et al. Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J Virol 2007;81:11703-11712.
38. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, Chung C, et al. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci USA 2009;106:9791-9796.
39. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
40. Kulkarni R, Hluhanich R, McColl DM, Miller MM, White KL. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother 2014;58:6145-6150.